• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Women who skip mammo face higher risk of death

Publication
Article
Diagnostic ImagingDiagnostic Imaging Vol 31 No 12
Volume 31
Issue 12

Older adult women who do not undergo regular screening mammography are more likely to die of breast cancer than women who are scanned, according to a long-term study of breast imaging in Massachusetts.

Older adult women who do not undergo regular screening mammography are more likely to die of breast cancer than women who are scanned, according to a long-term study of breast imaging in Massachusetts.

Dr. Blake Cady, professor emeritus of surgery at Harvard, and colleagues reviewed the cases of 6997 women who were diagnosed with invasive breast cancer between 1990 and 1999. All women also underwent follow-up through 2007. Cady confirmed 461 deaths, 116 for regularly screened women and 345 among women who were not regularly screened. Nearly two-thirds (60.9%) of deaths involved women who had never undergone screening while 5% occurred for those with at least one previous mammogram, but not within two years of diagnosis. The study was presented at the 2009 Breast Cancer Symposium in San Francisco.

Recent Videos
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 2
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.